SCHEMBL458035

SCHEMBL458035

CCc1cc[c]cc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10489456 0.83 TAAR1 (0.31)
SCHEMBL458616 0.82
SCHEMBL21268278 0.79 TYR (0.35)
SCHEMBL58401 0.78 GABRA1 (0.33)
SCHEMBL27920115 0.78 LIPG (0.37)
SCHEMBL27431762 0.77
SCHEMBL21194014 0.77
SCHEMBL7441308 0.77 LMNA (0.40)
SCHEMBL27938758 0.77 LIPG (0.40)
SCHEMBL27920121 0.77 LIPG (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4673977-B2 2011-04-20 JP claimed
US-7399761-B2 Phthalazine derivatives with angiogenesis inhibiting activity NOVARTIS AG (CH) 2008-07-15 US claimed
CN-1314681-C 2,3-diazanaphthalene derivatives with angiogenesis inhibiting activity NOVARTIS AG (CH) 2007-05-09 CN claimed
JP-2007506696-A 2007-03-22 JP claimed
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases FINK CYNTHIA A 2007-03-15 US claimed
CN-1886378-A 1,4-disubstituted isoquinilone derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases NOVARTIS AG (CH) 2006-12-27 CN claimed
EP-1667980-A1 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2006-06-14 EP claimed
EP-1165085-B1 PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES NOVARTIS AG (CH) 2006-06-14 EP claimed
CN-1660840-A Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2005-08-31 CN claimed
US-20050176711-A1 Phthalazine derivatives for treating inflammatory diseases BOLD GUIDO (CH) 2005-08-11 US claimed
US-20040180899-A1 Phthalazine derivatives with angiogenesis inhibiting activity NOVARTIS AG (CH) 2004-09-16 US claimed
US-20040142934-A1 Phthalazine derivatives for treating inflammatory diseases BOLD GUIDO (CH) 2004-07-22 US claimed
CN-1507444-A 2,3-diazanaphthalene derivatives with angiogenesis inhibiting activity ��˹��ŵ�� 2004-06-23 CN claimed
EP-1387836-A1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY Novartis AG (CH) 2004-02-11 EP claimed
US-6686347-B2 RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS NOVARTIS AG (CH) 2004-02-03 US claimed
US-20030013718-A1 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2003-01-16 US claimed
WO-2002090346-A1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 2002-11-14 WO claimed
CN-1367695-A Phthalazine derivatives for the treatment of inflammatory diseases NOVARTIS AG (CH) 2002-09-04 CN claimed
EP-1165085-A1 PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES Novartis AG (CH) 2002-01-02 EP claimed
WO-2000059509-A1 PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES NOVARTIS AG (CH) 2000-10-12 WO claimed